Conference call/Webcast Information Kyle Rose Vice President, Investor Relations Enovis Corporation +1-917-734-7450 investorrelations@enovis.com Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A link to a replay of the call will also be available on the Enovis website later that day. ABOUT ENOVIS Enovis Corporation (NYSE: ...

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A link to a replay of the call will also be available on the Enovis website later that day. Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webc ...

Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. ABOUT ENOVIS Investors and others should note that Enovis rou ...

Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the ...

Enovis (ENOV) recently introduced the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse by including modular and augmented baseplates. The new full-range solution adds bone-sparing baseplate, peripheral fixation and glenosphere options to the proven Reverse Shoulder Prosthesis (RSP) glenoid baseplate while maintaining simplicity and efficiency. The AltiVate Reverse Glenoid System, an important addition to Enovis' industry-leading AltiVate products, received FDA ...

snoofek/iStock via Getty Images A Slight Step Back In The Last Quarter Q2 Results Will Likely Be Similar Enovis Should Have What It Needs To Compete The Outlook The Bottom Line The performance of mid-cap medical device company Enovis (NYSE:ENOV) is getting harder and harder for me to understand. As I've said in past articles, I've never really loved this business, and I've found some of management's projections to be overly optimistic, but I do think there is a solid orthopedic device business here, and I f ...

The AltiVate Reverse® Glenoid System offers a modular baseplate with neutral and 15° wedge options, as well as multiple central compression screw lengths and diameters. The baseplate boss was designed to be more bonesparing than any other currently available baseplate with a comparable central through-screw design to minimize the volume of bone removed and preserve the glenoid vault. It also adds four new glenospheres to the already robust RSP® offering, giving surgeons a comprehensive selection to optimize ...

"We are very pleased to offer a modular, augmented baseplate based on the proven central screw fixation principle of our legacy Reverse Shoulder Prosthesis (RSP®) system2," said Louie Vogt, Group President of Enovis™ Reconstructive Business Group. "This addition to our market-leading AltiVate Reverse continues our long history of surgeon-driven innovation and commitment to exceptional patient outcomes." The first surgery using AltiVate Reverse® Glenoid was conducted by Dr. Mark Frankle at Tampa General Hosp ...

Enovis Corp ENOV Loading... On June 13, Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1. The company's stock fell around 28% over the past month and has a 52-week low of $110.45. RSI Value: 22.62 RGEN Price Action: Shares of Repligen fell 2.4% to close at $120.00 on Thursday. Benzinga Pro's real-time newsfeed alerted to latest RGEN's news. Read More: Over $28M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying Loading... The most oversold stocks in the healt ...

The Medical Info Systems industry has witnessed exponential growth thanks to the growing demand for contactless services. The need for a distant treatment option and a paperless environment has led to a tremendous upsurge in digital healthcare options. Added to this is the latest GenAI wave, which has significantly sped up the acceptance and usage of advanced digital healthcare and telemedicine on a global scale. Per GlobalData research, the use of AI in the medical device market is expected to witness a CA ...